Structure via PubChem · Public domain (PubChem)
ペガプタニブ
Sign in to saveAlso known as Pegaptanib Octasodium, NX1838, Pegaptanib sodium, EYE 001, NX 1838
Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing. Outside the US pegaptanib is marketed by Pfizer. Approval was granted by the U.S. Food and Drug Administration (FDA) in December 2004.
Chemical data
- Formula
- C20H40N3NaO10P
- Molecular weight
- 536.5 g/mol
- SMILES
- COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCOP(=O)(C)O)NC(=O)OCCOC.[Na]
- InChIKey
- HZXSQIHZPVCLDJ-LMOVPXPDSA-N
- Polar surface area
- 171 Ų
- H-bond donors
- 4
- H-bond acceptors
- 10
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2004
- Admin. routes
- parenteral
- Indications
- age-related macular degeneration, retinal vein occlusion, macular degeneration, wet macular degeneration
via ChEMBL · EBI
Research
688 papers- Pegaptanib.2006
- Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.Clinical therapeutics · 2006
- Pegaptanib sodium.Nature reviews. Drug discovery · 2005
- Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.The British journal of ophthalmology · 2007
- Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.Expert opinion on pharmacotherapy · 2005
via PubMed
Wikidata facts
- Mass
- 536.2349
- Has use
- medication
Show 5 more facts
- chemical formula
- C₂₀H₄₀N₃NaO₁₀P
- canonical SMILES
- COCCOC(=O)NCCCCC(C(=O)NCCCCCOP(=O)(C)O)NC(=O)OCCOC.[Na]
- NCI Thesaurus ID
- C90657
- isomeric SMILES
- COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCOP(=O)(C)O)NC(=O)OCCOC.[Na]
- has characteristic
- biopharmaceutical
Sources (2)
via Wikidata · CC0
Article · 日本語
ペガプタニブナトリウム（Pegaptanib sodium）注射剤（商品名：マクジェン）は、抗血管新生作用を有する滲出型加齢黄斑変性症（AMD）の治療薬である。本剤は、NeXstar Pharmaceuticals社（1999年にギリアド・サイエンシズ社と合併）によって発見され、2000年にEyeTech Pharmaceuticals社（現OSI Pharmaceuticals社）にライセンスされ、米国での後期開発および販売を行っている。ギリアド・サイエンシズ社は医薬品のライセンスからのロイヤルティを継続して受け取っている。米国外では、ペガプタニブはファイザー社が販売している。2004年12月に米国食品医薬品局（FDA）より承認を取得した。2008年7月には日本でも承認された。日本初の「核酸医薬」である。
Abstract from DBpedia / Wikipedia · CC BY-SA